Puma Biotechnology Inc (PBYI)
PBYI · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Signal Snapshot
11
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
3 Phase 1, 9 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-23. Source
Recent Publications
- Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab. — J Neurooncol (2026) PMID 42717134
- pH- and ROS-Responsive Polyurethane/Polylysine Nanomicelles Delivering Leonurine Attenuate Inflammation and Cartilage Damage in Experimental Rheumatoid Arthritis. — Int J Nanomedicine (2026) PMID 42699353
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Puma Biotechnology Inc.
Full PBYI Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.